Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing.
AuthorCoutelle, O; Hornig-Do, H-T; Witt, A; Andree, M; Schiffmann, LM; Piekarek, M; Brinkmann, K; Seeger, JM; Liwschitz, M; Miwa, S; ...
Source TitleEMBO Molecular Medicine
University of Melbourne Author/sBrinkmann, Kerstin
AffiliationMedical Biology (W.E.H.I.)
Document TypeJournal Article
CitationsCoutelle, O., Hornig-Do, H. -T., Witt, A., Andree, M., Schiffmann, L. M., Piekarek, M., Brinkmann, K., Seeger, J. M., Liwschitz, M., Miwa, S., Hallek, M., Krönke, M., Trifunovic, A., Eming, S. A., Wiesner, R. J., Hacker, U. T. & Kashkar, H. (2014). Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing.. EMBO Mol Med, 6 (5), pp.624-639. https://doi.org/10.1002/emmm.201303016.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023885
In the normal quiescent vasculature, only 0.01% of endothelial cells (ECs) are proliferating. However, this proportion increases dramatically following the angiogenic switch during tumor growth or wound healing. Recent evidence suggests that this angiogenic switch is accompanied by a metabolic switch. Here, we show that proliferating ECs increasingly depend on mitochondrial oxidative phosphorylation (OxPhos) for their increased energy demand. Under growth conditions, ECs consume three times more oxygen than quiescent ECs and work close to their respiratory limit. The increased utilization of the proton motif force leads to a reduced mitochondrial membrane potential in proliferating ECs and sensitizes to mitochondrial uncoupling. The benzoquinone embelin is a weak mitochondrial uncoupler that prevents neoangiogenesis during tumor growth and wound healing by exhausting the low respiratory reserve of proliferating ECs without adversely affecting quiescent ECs. We demonstrate that this can be exploited therapeutically by attenuating tumor growth in syngenic and xenograft mouse models. This novel metabolic targeting approach might be clinically valuable in controlling pathological neoangiogenesis while sparing normal vasculature and complementing cytostatic drugs in cancer treatment.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References